louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00139126: Research to Improve Smoke Alarm Functioning and Maintenance
Official title: Research to Improve Smoke Alarm Functioning and Maintenance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Wounds and Injuries
Burns
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
Collaborators: name: Pacific Institute for Research and Evaluation
First posted: 2005-08-31
Enrollment: 4500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study to evaluate whether (1) targeted smoke alarm education, (2) general fire safety education with a smoke alarm component, (3) basic fire safety education, or (4) an unrelated intervention is most effective way to improve smoke alarm maintenance and function.


Eligibility criteria: Inclusion Criteria:

* live within four target neighborhoods in Prince George's County, MD that are at high risk for residential fire and injury.

Exclusion Criteria:

* primary decision maker of home is less than 18 years old
* speak a language other than english or spanish
* nobody at home after six return visits to the home

Primary outcomes:
measure: Smoke alarm functionality post-intervention.
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Calverton
country: United States
facility: Pacific Institute for Research and Evaluation
state: Maryland
Study officials:
affiliation: Pacific Institute for Research and Evaluation
name: Les R Becker, PhD
role: STUDY_DIRECTOR
affiliation: Pacific Institute for Research and Evaluation
name: Ted R. Miller, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Miller TR, Bergen G, Ballesteros MF, Bhattacharya S, Gielen AC, Sheppard MS. Increasing smoke alarm operability through theory-based health education: a randomised trial. J Epidemiol Community Health. 2014 Dec;68(12):1168-74. doi: 10.1136/jech-2014-204182. Epub 2014 Aug 27.
Clinical trial NCT05279326: Virtual SMAs in Lifestyle Approach for Type 2 Diabetes
Official title: Virtual Shared Medical Appointments (SMAs) in Lifestyle Approach for Type 2 Diabetes: Protocol of a Randomized Pragmatic Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Diabetes Type 2
Lead sponsor: Universidade do Porto
Sponsor class: OTHER
Collaborators: name: Unidade de Saúde Familiar Homem do Leme
name: Health4All Primary Healthcare Research Network
First posted: 2022-03-15
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study protocol presents the design of a randomized pragmatic trial. This study aims to determine the effectiveness of virtual shared medical appointments (SMAs) lifestyle approach in improving glycaemic control, compared to usual care in type 2 diabetes (T2D) subjects.


Eligibility criteria: Inclusion Criteria:

* (1) be 18 years old or older
* (2) have a diagnosis of T2D with HbA1c ≥ 6.5% within the preceding 6 months
* (3) have body mass index (BMI) ≥ 25.0 kg/m2 within the preceding 6 months
* (4) have access to a camera and internet

Exclusion Criteria:

* unable to attend virtual SMAs for diagnosis of dementia or other cognitive impairment and any behavioral problem, which interferes with group participation and discussion
* not fluent in Portuguese, and unable to follow conversations, read instructions, and read in Portuguese
* being pregnant or planning a pregnancy in the next year
* attending a weight loss and/or physical activity counseling program

Primary outcomes:
measure: Change in glycaemic management, to be assessed by blood analysis
timeFrame: 12 months
Secondary outcomes:
measure: Change in weight, to be assessed by weight balance
timeFrame: 12 months
measure: Change in waist circumference, to be assessed by measuring tape
timeFrame: 12 months
measure: Change in systolic and diastolic blood pressure, to be assessed by sphygmomanometer
timeFrame: 12 months
measure: Change in fasting plasma triglycerides concentrations, to be assessed by blood analysis
timeFrame: 12 months
measure: Change in fasting plasma low density lipoprotein (LDL) concentrations, to be assessed by blood analysis
timeFrame: 12 months
measure: Change in fasting plasma high density lipoprotein (HDL) concentrations, to be assessed by blood analysis
timeFrame: 12 months
measure: Change in number of individual consultations, to be assessed by electronic health record
timeFrame: 12 months
measure: Change in use of medication, to be assessed by electronic health record
timeFrame: 12 months
measure: Change in the participants' satisfaction, to be assessed by questionnaire
timeFrame: 12 months
Other outcomes:
Locations:
city: Porto
country: Portugal
facility: Unidade de Saúde Familiar Homem do Leme
Study officials:
affiliation: Universidade do Porto
name: Rosalia Pascoa, MD, PhDc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00694226: Brief Intervention in Substance Use in Adolescent Psychiatric Patients
Official title: Brief Intervention in Substance Use Among Adolescent Psychiatric Patients: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Substance-Related Disorders
Keywords: Adolescent
Substance use
Brief intervention
Child psychiatry
Lead sponsor: Hospital Clinic of Barcelona
Sponsor class: OTHER
Collaborators: name: Ministry of Health, Spain
First posted: 2008-06-10
Enrollment: 143
Sex: ALL
Minimum age (years): 12
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the study was to assess the efficacy in decreasing the likelihood of substance use of a brief motivational enhancement intervention in adolescents referred to psychiatric treatment.

237 adolescents consecutively admitted to a psychiatry department completed an evaluation of their substance use. Subjects identified as users were randomly allocated to one of two groups: an experimental group that received a brief intervention aimed at increasing their awareness of the risks of substance use, or a control group. All subjects received standard treatment according to the primary diagnosis. Structured questionnaires assessing knowledge, attitudes, perception of risks and intention of use of psychoactive substances were administered upon admission and 1 month later.


Eligibility criteria: Inclusion Criteria:

* Subjects aged 12-17
* consecutively referred for psychiatric or psychological assessment and treatment to a Child and Adolescent Psychiatry and Psychology Department

Exclusion Criteria:

* Not willing to take part.
* Mentally retarded
* Non completion of a substantial part of the assessment protocol.
* Presenting severe acute psychopathological disturbances that interfere with the assessment.

Primary outcomes:
measure: Attitudes towards psychoactive substances (Knowledge, Risk perception, Problems and Intention of use) measured with questionnaires obtained from the Evaluation Instruments Bank (EIB), European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Clinic Barcelona
Study officials:
References:
Clinical trial NCT02047526: A Study to Evaluate the Clinical Epidemiology of Patients With Heart Failure (HF) in India
Official title: A Non-interventional, Prospective Study to Evaluate the Clinical Epidemiology of Patients With Heart Failure (HF) in India
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Heart Failure
Keywords: Heart Failure
Cardiovascular disease
Congestive Heart Failure
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2014-01-28
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients with Dyspnea and/or signs of systemic congestion

Brief summary: This non-interventional, prospective, multi-centric, cross-sectional study is aimed to observe clinical practice in India in managing Heart Failure patients \& to check one year outcome in HF patients. A total of 5 visits will be conducted during the study. There will be a baseline visit followed by four follow-up visits to assess the outcomes

Detailed description: A non-interventional, prospective study to evaluate the clinical epidemiology of patients with Heart Failure (HF) in India

Eligibility criteria: Inclusion Criteria:

1. Provision of subject informed consent
2. Female or male aged 18 years and over
3. All patients with Dyspnea and/or signs of systemic congestion

Exclusion Criteria:

1. Subjects with Current Acute Coronary Syndrome
2. Absence of cardiac disease/structural heart disease

Primary outcomes:
measure: Cardiovascular hospitalization rates and Length of stay
timeFrame: 1 year
measure: HF related Hospitalization and hospital visits
timeFrame: 1 year
measure: Cardiovascular and all cause mortality
timeFrame: 1 year
measure: Change in Minnesota Living with Heart Failure Questionnaire scores.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: AstraZeneca Pharma India Ltd.
name: Ammar Raza, MBBS, DIP DIAB, MBA
role: STUDY_DIRECTOR
affiliation: Medanta, The Medicity, Gurgaon
name: R R Kasliwal, DM
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03234426: Effectiveness of Perturbations Exercises in Improving Balance, Function and Mobility in Stroke Patients
Official title: Effectiveness of Perturbations Exercises in Improving Balance, Function and Mobility in Stroke Patients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Lead sponsor: Mahatma Gandhi Institute of Medical Sciences
Sponsor class: OTHER
First posted: 2017-07-31
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Following stroke, patients loses functions of the motor, sensory and higher brain cognitive faculties to various degrees which lead to diminished balance. It has been documented that hemiplegic or hemiparetic stroke patients presented with more posture sway, asymmetric weight distribution, impaired weight-shifting ability and decreased stability capability. There are many balance exercises and strategies; to improve balance in elderly age group population, to prevent fall prevention. But we have very few evidences of giving manual perturbation balance training in stroke patients to improve speed, balance and function. Therefore this study is taken up to examine whether the manual perturbation balance training is more effective in improving speed, balance and function in stroke patients.

Detailed description: There are many more studies done for elderly populations, normal individuals for improving balance by giving perturbation based balance training.All perturbation exercises are given by either mechanical or by self reaching tasks in forward,backward,and in both sideways. There are very studies ;who attempted perturbation based balance training to improve balance in elderly population but not for stroke patients for their Speed, Balance and Function.The manual perturbation exercise can be an promising intervention in the future for various conditions

Eligibility criteria: Inclusion Criteria:

1. First ever stroke
2. Age ranges between 40-70
3. Both genders were included
4. Ambulatory patients with or without ambulatory aids
5. Occurrence of stroke at within 0-3 months i.e.-sub acute
6. Able to follow command
7. Mini mental scale examinations not less than 24

Exclusion Criteria:

1. Patients who has severe limitations in passive range of motion at lower extremities
2. Patients with impaired sensory, proprioceptor, cognitive and perceptual ability
3. Patient who has contracture
4. Orthopedic or any other neurological disorder which impair balance

Primary outcomes:
measure: Berg Balance Scale
timeFrame: 4 weeks
Secondary outcomes:
measure: Functional Independence Scale
timeFrame: 4 weeks
Other outcomes:
measure: Timed Up and Go Test
timeFrame: 4 weeks
Locations:
city: Aurangabad
country: India
facility: MGM school Of Physiotherapy
state: Maharashtra
Study officials:
affiliation: MGM School Of Physiotherapy,Aurangabad,Maharashtra, India
name: Nawaj Pathan, PG student
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03849326: Chronic Fatigue Etiology in Intensive Care Unit Survivors: the Role of Neuromuscular Function
Official title: Chronic Fatigue Etiology in Intensive Care Unit Survivors: the Role of Neuromuscular Function
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Chronic Fatigue Syndrome
Intensive Care Unit
Muscle
Keywords: Neuromuscular function
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
Collaborators: name: University of Saint-Etienne
First posted: 2019-02-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Chronic fatigue is the most common and debilitating symptom in intensive care unit (ICU) survivors. Indeed, it has been widely reported that patients who stayed in ICU for prolonged periods report a feeling of tiredness for months to years after ICU discharge. This chronic fatigue affects their quality of life by decreasing their capacity to perform simple tasks of daily life.

The aim of the present project is to determine whether deteriorated neuromuscular function (i.e. increased fatigability) is involved in this feeling of chronic fatigue. Because the causes of this feeling are multi-dimensional, a large battery of tests will allow us to better understand the origin of chronic fatigue. A better knowledge of chronic fatigue etiology will allow to optimize rehabilitation treatments to decrease the apparition/persistence of chronic fatigue and in fine improve life quality.


Eligibility criteria: Inclusion Criteria:

* Have been ventilated for at least 72 hours in the intensive care unit
* IGS2 score (severity in resuscitation) \> 15
* FACIT-F (Functional Assessment of Chronic Illness Therapy-Fatigue) score ≥ 36 or a score ≤ 32
* intensive care unit discharge in ≥ 6 months and ≤ 5 years preceding the study
* Approval received from a physician
* Command of the French language

Exclusion Criteria:

* Taking neuroactive substances that can alter corticospinal excitability
* Contraindication to the application of a magnetic field
* Contraindication to the practice of Magnetic Resonance Imaging
* Participant is pregnant
* Patients with psychiatric disorders
* Paraplegic and hemiplegic patients
* Addictive disorders

Primary outcomes:
measure: voluntary maximum force reduction
timeFrame: at 2 weeks
Secondary outcomes:
measure: Neuromuscular function : cortical activity
timeFrame: at 2 weeks
measure: Neuromuscular function : Peripheral function
timeFrame: at visit 2
measure: Maximal oxygen uptake (VO2max)
timeFrame: at 2 weeks
measure: quality of sleep
timeFrame: at baseline
measure: Quadriceps muscle volume (optional)
timeFrame: at 3 weeks
measure: muscle dysfunction (optional)
timeFrame: at 3 weeks
Other outcomes:
Locations:
city: Saint-Étienne
country: France
facility: Hôpital privé de la Loire
Study officials:
affiliation: CHU de Saint Etienne
name: Jérome MOREL, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04132726: Effect of Massage Treatment in Temporomandibular Joint
Official title: Effect of Massage Treatment in Patients With Temporomandibular Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Massage Therapy
Temporomandibular Disorder
Keywords: Massage
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2019-10-21
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Temporomandibular disorders (TMD) have multiple and broad clinical effects on orofacial structures and are often diagnosed in patients with a prevalence of between 5% and 12%. Among treatment options, massage therapy is one of the common therapeutic procedures and allows interesting clinical outcomes by reducing TMD symptoms successfully. However, there has been no attempt to validate this knowledge. Thus, the aim of this study is to evaluate the effect of massage and its properties in patients with TMD.


Eligibility criteria: Inclusion Criteria:

1. Temporomandibular disorder-positive RDC/TMD examination for groups RDC/TMD Ia and RDC/TMD Ib,
2. Patient agreement to participate in the experimental study.

Exclusion Criteria:

1. RDC/TMD II and RDC/TMDIII,
2. Drug and/or removable partial or total prosthesis wearers,
3. Being submitted to any type of physiotherapeutic treatment,
4. Incomplete dentition,
5. History of systemic diseases as diabetes or arthritis,
6. The occurrence of facial trauma,
7. Refusal to assume responsibility with this research.

Primary outcomes:
measure: Pain- Visual Analog Scale
timeFrame: 12 weeks-14 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Fatih
country: Turkey
facility: Istanbul university,Faculty of Dentistry
Study officials:
affiliation: Istanbul University
name: Merve Benli, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Capellini VK, de Souza GS, de Faria CR. Massage therapy in the management of myogenic TMD: a pilot study. J Appl Oral Sci. 2006 Jan;14(1):21-6. doi: 10.1590/s1678-77572006000100005.
Clinical trial NCT01079026: Outcome After Lumbar Epidural Steroid Injection
Official title: Functional Outcome After Lumbar Epidural Steroid Injection
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Disc Disease
Keywords: biomarker
epidural steroid
radiculopathy
hnp
Lead sponsor: Scuderi, Gaetano J., M.D.
Sponsor class: OTHER
Collaborators: name: Cytonics Corporation
First posted: 2010-03-02
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients considered candidates for ESI were 18 years of age or greater with a history of leg sensory complaints primarily dictated by pain with associated sensory symptoms and/or low back pain for two weeks or more who had failed expectant management with NSAIDS, activity modification, and/or physical therapy.

Brief summary: prospectively validate a fibronectin-aggrecan complex as a biomarker for response to ESI for radiculopathy with HNP

Detailed description: We will measure levels of the protein complex in the epidural space of patients undergoing lumbar ESI for radiculopathy with HNP. We assess functional outcomes at baseline and after treatment with the Medical Outcomes Study Short Form-36 instrument (SF-36). Our hypothesis was that the complex is present in patients with clinically significant functional improvement after ESI.

Eligibility criteria: Inclusion Criteria:

* Acute onset of sensory symptoms with the primary complaint as pain as well as varying sensory symptoms (e.g. tingling, numbness) in one or more lumbar nerve root distributions
* Positive physical exam findings including sensory findings consistent with a spinal nerve root, a positive straight leg raise test, and/or a diminished patellar or Achilles DTR consistent with sensory symptoms; AND
* MRI of lumbar spine positive for HNP in a distribution correlating with physical examination

Exclusion Criteria:

* Plain radiography demonstrating severe loss of disc height, high grade DDD, spondylolisthesis greater than grade I
* A history of prior lumbar surgery or trauma, weakness in a consistent distribution (non-progressive with strength at least 4/5)
* Red flags including progressive weakness, bowel/bladder complaints, radiographic unknown mass, unexpected weight loss; AND
* Diagnosis of inflammatory arthritides, crystalline arthropathies, or other rheumatologic diseases

Primary outcomes:
measure: functional outcome on SF-36 following ESI
timeFrame: 2-6 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Stanford University
name: Gaetano J Scuderi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06125457: Epidemiology of IgA Selective Deficiency - Clinical Manifestations and Risk of Transmission
Official title: Epidemiology of IgA Selective Deficiency - Clinical Manifestations and Risk of Transmission: A Retrospective Cohort Study in Strasbourg University Hospital
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: COVID-19
Keywords: COVID-19
IgA deficiency
Antibiotic therapy
Immunosuppressive treatments
Autoimmune manifestations
Neoplasia
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2023-11-09
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Major subject (≥18 years old) with a primary selective IgA deficiency treated at the HUS from 01/01/2005 to 01/31/2022

Brief summary: The management of patients with a selective IgA deficiency currently consists of symptomatic treatment with treatment of infections by occasional or prolonged antibiotic therapy, immunosuppressive treatments for autoimmune pathologies, symptomatic treatment of allergic manifestations.

IVIG supplements are sometimes proposed in the event of recurrent infections and the demonstration of deficiencies in IgG subclasses (IgG1, 2, 3) often not sought for diagnosis The factors associated with the severity of clinical manifestations are not well identified and patients with IgA deficiency must be monitored over the long term because of the risk of the appearance of autoimmune manifestations and neoplasia. The identification of such factors could lead to the proposal of close monitoring for these patients.

IgA deficiency, which is frequent, has not been identified as a risk factor for severe COVID-19 infection, probably due to a lack of studies with sufficient recruitment. The therapeutic attitude concerning patients with an IgA deficiency in the event of COVID-19 infection is therefore not consensual.

There is currently no action to be taken regarding the risk of transmission of IgA deficiency.


Eligibility criteria: Inclusion criteria:

* Major subject (≥18 years old)
* Subject treated at the HUS, with a primary selective IgA deficiency, considered as definitive (IgA concentration \< 0.07g/L or total absence of IgA on immunofixation) or as probable (IgA concentration lower than two standard leads to standard for age) with no other humoral immunodeficiency and no other cause of decreased gammaglobulins 01/01/2005 to 01/31/2022.
* Subject having not expressed, after being informed, their opposition to the reuse of their data for the purposes of this research.

Exclusion criteria:

. Subject who expressed their opposition to participating in the study

Primary outcomes:
measure: Positive test result for covid-19
timeFrame: 1 hour after hospitalization
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service d'Immunologie Clinique - Médecine Interne - CHU de Strasbourg - France
Study officials:
References: